Poster Presentation Australian Diabetes Society and the Australian Diabetes Educators Association Annual Scientific Meeting 2016

Cost Effectiveness of FreeStyle Libre® Flash Glucose Monitoring System from an Australian Health Care Payer Perspective (#308)

Richard Hellmund 1 , Matt Kirchmann 2 , Kelly Makarounas-Kirchmann 2 3
  1. Abbott Diabetes Care, Alameda, California , USA
  2. KMC Health Care, Frankston South, VIC, Australia
  3. Department of Epidemiology & Preventative Medicine, Monash University, Melbourne, Victoria, Australia


The IMS Core Diabetes Model (CDM) was utilised to assess the cost-effectiveness of FreeStyle Libre® Flash Glucose Monitoring System (FreeStyle Libre System) vs. Self-Monitoring Blood Glucose (SMBG) in the Australian clinical setting, using a health care payer perspective.  FreeStyle Libre System is a novel, sensor-based, factory-calibrated monitoring system that continuously measures glucose levels in the interstitial fluid using wired enzyme technology.  Data is wirelessly transferred from the 14-day adhesive sensor to a handheld reader. 


The IMPACT randomised clinical trial provided key inputs to the IMS-CDM.  It assessed the efficacy and safety of the FreeStyle Libre System in people with T1DM over 6 months and reflected real-world clinical practice in 120 people using the FreeStyle Libre System compared to 121 using SMBG.  Literature derived utilities and a Sponsor commissioned Time-Trade-Off (TTO) study (1) were incorporated.  The TTO study reported utilities of 0.882 vs 0.851 (p<0.0001), favouring the FreeStyle Libre System.  A diminishing disutility associated with non-severe hypoglycaemic events (those not requiring 3rd party assistance) was applied (2).  The model horizon was 50 years, with 5% annual discounting.  Only direct costs were included. 


The IMS-CDM showed a total of 9.74 QALYs using the FreeStyle Libre System, resulting in a base case ICER of A$39,786 per QALY which is within Australian cost-effectiveness thresholds. 


The FreeStyle Libre System is a cost-effective method of monitoring glucose in Australia.

Declarations: R. Hellmund is an employee of Abbott Diabetes Care.  KMC Health Care were engaged by Abbott Diabetes Care to conduct this study.

  1. Matza L.S. DEW, Hellmund R., Polonsky W.H., Kerr D. Health state utilities associated with glucose monitoring devices. ISPOR 18th Annual European Congress; Milan, Italy 2015.
  2. Lauridsen JT. Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries. Qual Life Res. 2014;23(9):2645-50.